Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen

Menopause

Volumn 6, Issue 2, 1999, Pages 98-104

  Farish, Elizabeth ^a   Barnes, Judith F ^a   Fletcher, Colin D ^a   Ekevall, Klara ^a   Calder, Ann ^a   Hart, David M ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Apolipoproteins; HDL subfractions; Hormone replacement; Lipoprotein (a); Lipoproteins; Postmenopausal

Indexed keywords

CONJUGATED ESTROGEN; NORGESTREL; TIBOLONE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033035087     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-199906020-00005     Document Type: Article

References (33)

1. Farish E, Fletcher CD, Hart DM, Teo C, Alazzawi F, Howie C. The effects of conjugated equine oestrogens, with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women. Acta Endocrinol 1986;113:123-7.
2. Benedek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas 1987;(Suppl. 1):25-33.
3. Lindsay R, Hart DM, Kraszewski A. A prospective double-blind trial of synthetic steroid (ORG OD 14): for preventing postmenopausal osteoporosis. Br Med J 1980;280:1207-9.
4. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD 14 and the endometrium. Maturitas 1991;13:243-51.
5. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson J. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993;128:259-62.
6. Haenggi W, Riesen W, Birkhaeuser MH. Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein (a). Eur J Clin Chem Clin Biochem 1993;31:645-50.
7. Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1995;20:215-9.
8. Farish E, Fletcher CD, Hart DM, Lindsay R, Leggate J. Org OD 14: long term effects on serum lipoproteins. Maturitas 1984;6:297-9.
9. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long term effects of Org OD 14 on lipid metabolism in postmenopausal women. Maturitas 1990;12:37-42.
10. Jensen J. Sex steroids and serum lipids and lipoproteins. In: Christiansen C, ed. Bailliere's Clinical Obstetrics and Gynaecology. Hormone replacement and its impact on osteoporosis. London and Philadelphia: Baillière Tindall, 1991;5:867-87.
11. Crona N, Silfverstolpe G, Samsoie G. A double-blind crossover study on the effects of ORG OD 14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomised women. Acta Endocrinol (Copenh) 1983;102:451-5.
12. Bengtsson C, Bjorkelund C, Lapidus L, Lissner L. Association of serum lipid concentrations and obesity with mortality in women: 20-year follow-up of participants in a prospective population study in Gothenburg, Sweden. Br Med J 1993;307:1385-8.
13. Fruchart JC, Packard CJ. Is cholesterol the major lipoprotein risk factor in coronary heart disease? - a Franco-Scottish Overview. Curr Med Res Opin 1997;13:603-16.
14. Labeur C, De Bacquer D, De Backer G, et al. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem 1992;38:2261-6.
15. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chestnut CH, Hazzard WR. Reduction of lecithin-cholesterol acyl transferase, apolipoprotein B and the Lp(a) lipoproteins with the anabolic steroid stanozolol. Biochim Biophys Acta 1984;795:293-6.
16. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. Br Med J 1991;303:694.
17. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
18. Farish E, Spowart K, Barnes JF, et al. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis 1996;126:77-84.
19. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994;343 :75-9.
20. Fletcher CD, Barnes JF, Farish E. A rapid semi-micro method for the separation of lipoprotein fractions that uses a benchtop ultracentrifuge. Clin Chim Acta 1994;226:95-9.
21. De Aloysio D, Fabiani AG, Mauloni M, Bottiglioni P. Use of Org OD 14 for the treatment of climacteric complaints. Maturitas 1987;1(SuppI.):49-65.
22. Bjarnason NH, Bjarnason K, Haarbo H, Bennink HJTC, Christiansen C. Tibolone: Influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6.
23. Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen/progestin. Obstet Gynecol 1996;87:593-9.
24. Cheung MC, Albers JJ. The measurement of apolipoprotein AI and All levels in men and women by immunoassay. J Clin Invest 1977;60:43-50.
25. Hanggi W, Lippuner K, Reisen W, Jaeger P, Birkhauser MH. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997;104:708-17.
26. Miller VT, Muesing RA, LaRosa JC, Stoy DR, Phillips EA, Stillman RJ. Effects of conjugated equine oestrogen with three different progestogens on lipoproteins, high-density lipoprotein subfractions and apolipoprotein AI. Obstet Gynecol 1991;77:235-40.
27. Crook D, Cust MP, Ganger KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-5.
28. Fletcher CD, Farish E, Dagen MM, Hart DM. Short-term changes in lipoproteins and apoproteins during cyclical oestrogen-progestogen replacement therapy. Maturitas 1991;14:33-42.
29. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
30. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
31. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
32. Griffin B, Farish E, Walsh D, et al. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol 1993;39:463-8.
33. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993;42:1153-8.